Free cash flow remains erratic, swinging from a positive $8.2 million in 2023Q4 to a negative $10.6 million in 2026Q1, largely driven by volatile working capital requirements.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Cash from Operations | -13.37M | -13.63M | -13.28M | -14.46M | -32.14M | -20.27M | -14.08M | -9.71M | -9.3M | -10.97M | -11.9M | -10.77M | -6.87M | -7.48M |
| Operating CF Margin % | - | -20.47% | -23.87% | -27.52% | -70.55% | -41.97% | -33.55% | -24.04% | -28.67% | -40.91% | -66.32% | -92.37% | -224.71% | -807.45% |
| Operating CF Growth % | -711.27% | -2.61% | 8.18% | 55.01% | -58.59% | -43.92% | -45.03% | -4.41% | 15.2% | 7.85% | -10.48% | -56.93% | 8.19% | - |
| Net Income | -20.17M | -19.95M | -15.12M | -23.69M | -47.39M | -26.85M | -16.69M | -12.04M | -8.01M | -25.63M | -19.18M | -14.98M | -13.5M | -7.32M |
| Depreciation & Amortization | 2.28M | 2.12M | 1.72M | 2.17M | 1.56M | 948K | 546K | 591K | 731K | 670K | 879K | 558K | 455K | 398K |
| Stock-Based Compensation | 1.69M | 2.16M | 1.76M | 3.62M | 4.7M | 4.73M | 2.69M | 572K | 114K | 187K | 287K | 279K | 152K | 116K |
| Deferred Taxes | 0 | 0 | 0 | 0 | -306K | 148K | -106K | -247K | 31K | -554K | 251K | -14K | 42K | 42K |
| Other Non-Cash Items | 4.46M | 4.03M | 1.43M | 3.12M | 7.62M | 819K | 805K | 1.24M | 1.43M | 16.38M | 6.76M | 1.71M | 5.22M | -263K |
| Working Capital Changes | -1.63M | -1.98M | -3.08M | 325K | 1.67M | -61K | -1.34M | 174K | -3.59M | -2.02M | -896K | 1.68M | 759K | -446K |
| Change in Receivables | -1.04M | -3.02M | -1.28M | -474K | 3.58M | -744K | -3.19M | 237K | -2.26M | -198K | 0 | 55K | -55K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -567K | -497K | 436K | 0 | 261K | 403K | 0 |
| Change in Payables | -230K | 42K | 308K | 67K | 901K | -655K | 986K | 528K | -824K | 44K | 77K | 1.4M | 381K | -549K |
| Cash from Investing | -747K | -626K | -515K | -804K | -4.32M | -2.42M | -455K | -103K | -199K | -510K | -800K | -649K | 549K | -1.13M |
| Capital Expenditures | -756K | -641K | -515K | -828K | -4.32M | -2.37M | -455K | -403K | -199K | -567K | -805K | -649K | -172K | -440K |
| CapEx % of Revenue | 1.11% | 0.96% | 0.93% | 1.58% | 9.48% | 4.91% | 1.08% | 1% | 0.61% | 2.12% | 4.49% | 5.56% | 5.63% | 47.52% |
| Acquisitions | 9K | 15K | 0 | 0 | 0 | 0 | 0 | 300K | 0 | 57K | 5K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 24K | 0 | -50K | 0 | 0 | 0 | 57K | 5K | 0 | 721K | -693K |
| Cash from Financing | 24.44M | 24.43M | -663K | -10.63M | -489K | 64.68M | -97K | 68.73M | 11.42M | 19.16M | 10.61M | 8.28M | 11.31M | 7.25M |
| Debt Issued (Net) | 1.92M | 2.01M | -861K | -10.94M | -696K | -525K | -249K | -138K | 4.96M | 4.51M | 10.75M | 8.72M | 7.4M | -550K |
| Equity Issued (Net) | 22.52M | 22.42M | 198K | 306K | 446K | 69.14M | 173K | 68.87M | 0 | 0 | 4K | 195K | 0 | 7.8M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6.74M | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | -239K | -3.94M | -21K | 6.74M | 6.47M | 14.64M | -147K | -635K | 3.91M | 0 |
| Net Change in Cash | 10.32M | 10.18M | -14.46M | -25.9M | -36.95M | 41.99M | -14.64M | 58.92M | 1.92M | 7.68M | -2.1M | -3.14M | 5M | -1.36M |
| Free Cash Flow | -14.13M | -14.27M | -13.79M | -15.29M | -36.46M | -22.64M | -14.54M | -10.11M | -9.5M | -11.54M | -12.71M | -11.42M | -7.04M | -7.92M |
| FCF Margin % | -20.66% | -21.43% | -24.79% | -29.1% | -80.03% | -46.87% | -34.64% | -25.04% | -29.28% | -43.03% | -70.81% | -97.93% | -230.34% | -854.97% |
| FCF Growth % | 8.57% | -3.42% | 9.78% | 58.07% | -61.06% | -55.71% | -43.75% | -6.46% | 17.64% | 9.22% | -11.25% | -62.31% | 11.12% | - |
| FCF per Share | -0.59 | -0.66 | -0.76 | -0.86 | -2.13 | -1.42 | -1.15 | -0.81 | -150.78 | -183.08 | -202.35 | -202.65 | -131.10 | -223.61 |
| FCF Conversion (FCF/Net Income) | 0.70x | 0.68x | 0.88x | 0.61x | 0.68x | 0.75x | 0.84x | 0.81x | 1.16x | 0.43x | 0.62x | 0.72x | 0.51x | 1.02x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Limited operational cash runway
As reported in recent financial filings, Exagen's operating cash flow frequently diverges from net income, with OCF/NI ratios reaching as high as 2.84 in 2025Q1, suggesting that reported earnings are significantly impacted by non-cash adjustments and timing differences in revenue recognition rather than actual cash generation.
The persistent gap between net income and operating cash flow indicates that the company's accrual-based accounting may be masking the underlying cash burn. Investors should monitor whether these fluctuations in conversion are driven by legitimate timing differences in insurance collections or if they reflect a more structural difficulty in converting diagnostic service revenue into realized cash.
Based on the provided quarterly data, Exagen's free cash flow trajectory remains highly erratic, swinging from a positive $8.2 million in 2023Q4 to a negative $10.6 million in 2026Q1, which highlights the company's ongoing struggle to achieve a self-sustaining cash flow profile amidst its current growth phase.
The lack of a consistent positive FCF trend suggests that the business model is currently dependent on external capital to bridge the gap between operational expenses and cash receipts. This volatility warrants further investigation into whether the periodic cash inflows are sustainable or merely artifacts of lumpy insurance reimbursement cycles.
According to the cash flow statements, working capital changes have been a primary driver of cash volatility, with a significant $8.1 million outflow in 2025Q1 contrasting with a $10.9 million inflow in 2023Q4, indicating that the company's cash position is highly sensitive to accounts receivable management.
These dramatic swings in working capital suggest that the timing of insurance payments and the complexity of the billing process are creating significant friction in cash conversion. The reliance on these fluctuations to manage liquidity may indicate that the company lacks the operational maturity to stabilize its cash cycle.
As evidenced by the quarterly data, Exagen maintains a low capital intensity, with CapEx/Revenue ratios consistently remaining below 2% over the last ten quarters, suggesting that the company's primary cash requirements are operational rather than driven by heavy investment in physical laboratory infrastructure or equipment.
While the low capital intensity is a positive for cash preservation, it also implies that the company's growth is not being constrained by physical capacity but rather by the high cost of customer acquisition and service delivery. This structure suggests that any future scaling will likely require increased SG&A spend rather than significant capital expenditure.
Quick answers to the most common questions about buying XGN stock.
Exagen Inc. (XGN) generated $-13.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Exagen Inc. (XGN) reported negative free cash flow of $14.3M in 2025, indicating capital requirements exceeded cash from operations.
Exagen Inc. (XGN) spent $0.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.